Novel markers to improve detection of CIN in HPV immunised women
Research type
Research Study
Full title
Identification of novel disease markers to Improve detection of CIN in HPV immunised women
IRAS ID
223308
Contact name
Emmanouil Kalampokas
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
HPV vaccination should reduce the risk of cervical cancer by 70%. The UK HPV immunisation programme started in 2008 and upake in Scotland, has been high (>91%1). It does not protect against all cervical cancers so screening remains essential. The falling incidence of Cervical Intraepitelial Neoplasia (CIN) is already impacting on current detection methods. The changing profile of prevalent HPV subtypes in the popultaion may also impact on the natural history of disease and accurate detection of high grade CIN which is destined to progress. \nIn young women, we have already shown in Scotland that3: \n1.\tMultiple infections with non-vaccine high-risk HPV(hrHPV) types are common.\n2.\tImmunised women have lower rates of hrHPV infection, high-grade cytology and CIN2+.\n3.\tAn urgent review of referral criteria is required to maintain high quality colposcopy and avoid disbenefits.\nWe propose an exploratory study of HPV vaccinated women referred to colposcoy with abnormal cytology or test high-risk HPV positive. We will undertake detailed molecular profiling of HPV infection and associated markers of infection at the mRNA and protein level. The results of molecular assays will be compared to the current means of disease detection by cytology, colposcopy and histology. We will determine whether specific molecular signatures are associated with vaccinated women compared to unvaccinated women.\n
REC name
North of Scotland Research Ethics Committee 1
REC reference
17/NS/0043
Date of REC Opinion
19 May 2017
REC opinion
Further Information Favourable Opinion